Web Stats Provided By Google Analytics

Wednesday, July 10, 2013

Inovio's CELLECTRAA Electroporation Delivery Technology Powers...

The studies were conducted by the HIV Vaccine Trials Network . Inovio's HIV DNA vaccine together with the CELLECTRA device significantly increased the number of responders producing robust and durable CD4 and CD8 T-cell responses in humans.

http://www.sys-con.com/node/2730687

No comments:

Post a Comment